Advanced Proteome Therapeutics Corporation
APTCF · OTC
7/31/2022 | 7/31/2021 | 7/31/2020 | 7/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.25 | -9.49 | 0.93 |
| FCF Yield | -20.11% | -0.62% | -2.11% | -3.61% |
| EV / EBITDA | -3.53 | -136.19 | -39.62 | -21.43 |
| Quality | ||||
| ROIC | 186.68% | -1,265.01% | 61.50% | 151.20% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -1.16 | 0.28 | 0.86 | 1.49 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -29.34% | -17.12% | 32.04% | 43.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | 0.77 | -0.52 | -0.07 |
| Interest Coverage | -32.34 | -23.74 | -19.30 | -40.33 |
| Efficiency | ||||
| Inventory Turnover | -199.87 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -19,974.32 | -18,144.43 | -2,799.01 | -2,349.73 |